STOCK TITAN

Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends
Rhea-AI Summary

Avid Bioservices, Inc. (NASDAQ:CDMO, CDMOP) has announced a quarterly cash dividend of $0.65625 per share on its 10.50% Series E Convertible Preferred Stock. The dividend will be payable on April 1, 2021, to holders of record by March 15, 2021. This payment reflects an annualized rate of 10.50%, based on a liquidation preference of $25.00 per share. Avid Bioservices specializes in biologics contract development and manufacturing with extensive experience in the biotechnology sector.

Positive
  • Quarterly dividend of $0.65625 per share on Series E Preferred Stock.
  • Annualized dividend rate of 10.50% boosts shareholder income.
Negative
  • None.

TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").

The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2021 to holders of record at the close of business on March 15, 2021.

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2021 through March 31, 2021. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "CDMOP".

About Avid Bioservices, Inc.

Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com


FAQ

What is the dividend amount for Avid Bioservices' Series E Preferred Stock?

The quarterly dividend is $0.65625 per share.

When is the dividend payment date for Avid Bioservices?

The dividend is payable on April 1, 2021.

What is the significance of the 10.50% dividend rate for CDMOP?

The 10.50% rate is based on a liquidation preference of $25.00 per share, enhancing shareholder returns.

Who is eligible to receive the dividend payment from Avid Bioservices?

Holders of record by March 15, 2021, are eligible for the dividend payment.

Avid Bioservices, Inc.

NASDAQ:CDMO

CDMO Rankings

CDMO Latest News

CDMO Stock Data

646.24M
63.80M
1.14%
104.78%
20.68%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
TUSTIN